NYU Langone Insights on Psychiatry

Katlyn Nemani, MD, explores how autoimmune and inflammatory brain disorders can present as first-episode psychosis—and why some patients diagnosed with schizophrenia may actually have a treatable immune-mediated illness. She explains the clinical features that should prompt suspicion for autoimmune psychosis, including subacute onset, subtle neurologic signs, and poor response to antipsychotics, even when standard imaging and antib...

Lindsey Gurin, MD, discusses how clinicians can approach patients whose symptoms fall at the intersection of psychiatry and neurology. Drawing on her work with traumatic brain injury, PTSD, and persistent post-concussive symptoms, she explains why attempts to separate psychological trauma from neurological injury often obscure what patients actually need.

The conversation explores identity disruption after brain injury, the unintend...

Michael Bogenschutz, MD, explains how psychedelic-assisted treatments may offer new options for patients with severe, treatment-refractory psychiatric conditions. He discusses why standard approaches often fall short for complex cases, how psychedelics like psilocybin and MDMA differ from conventional medications, and what careful screening and clinical structure make these treatments safe and effective.

Drawing on randomized clinic...

Lenard Adler, MD, explains how clinicians can safely and effectively treat ADHD when bipolar disorder and addiction are also in the picture. He addresses how to distinguish chronic ADHD symptoms from episodic mood disorders, why bipolar disorder is often missed in adults referred for depression or attention problems, and how substance use complicates both diagnosis and medication selection.

Dr. Adler also shares guidance on identify...

Ayana Jordan, MD, PhD, discusses how precision psychiatry must expand beyond biology to address the social, cultural, and structural realities shaping addiction and mental health care for historically underrepresented patients. The conversation explores how trauma, poverty, housing instability, health literacy, and stigma interact with substance use and serious mental illness—and why traditional clinic-based models often fail to me...

Dan Iosifescu, MD, discusses why bipolar depression and mixed episodes remain among the most difficult—and highest-risk—conditions in psychiatry. Even when mood symptoms improve, many patients continue to experience significant cognitive and functional impairment. Dr. Iosifescu argues that standard approaches often fall short because symptom suppression is mistaken for recovery, short-term improvement is confused with durable treat...

Joshua Berman, MD, PhD, discusses how careful evaluation, patient priorities, and risk-benefit tradeoffs guide the use of interventional treatments when conventional approaches fall short. Dr. Berman also explains how tools such as ketamine, TMS, ECT, and neurofeedback can be used strategically—sometimes in sequence or combination—to address different vulnerabilities within mood-related brain circuits.

Dr. Berman is Associate Profes...

To kick off Season 4, Charles Marmar, MD, explains how precision psychiatry is reshaping the way clinicians and researchers think about diagnosis, treatment selection, and the underlying biology of psychiatric disorders. This conversation is a overview of where the field stands today—including emerging molecular markers, biologically informed subtypes, and new translational approaches inspired by oncology and other precision-based ...

What if mental health care worked more like cancer treatment—tailored to the individual, informed by biology, and driven by data? Charles Marmar, MD, Chair of Psychiatry at NYU Grossman School of Medicine, takes us through the latest advances in precision psychiatry. From brain imaging to digital phenotyping, Dr. Marmar outlines the tools shaping a future where treatment is fully customized. He also shares stories from the front li...

There’s a care model for schizophrenia that actually works—why isn’t it everywhere? On this episode, W. Gordon Frankle, MD, MBA, Vice Chair of Psychiatry at NYU Langone Health, shares how his team in Brooklyn is building a new model for treating serious mental illness—one rooted in long-term, relationship-driven, team-based care. From wraparound services to precision psychiatry, this conversation explores what happens when you brin...

How could a single psychedelic treatment cause lasting change? Joshua Siegel, MD, PhD, is on a mission to find out. A leading expert on neuroimaging and neuropsychopharmacology at NYU Langone’s Center for Psychedelic Medicine, Dr. Siegel unpacks how psilocybin may spark neuroplasticity and reshape the depressed brain. He also gives us an inside look at the race to develop non-hallucinogenic psychedelic analogs. 

Dr. Siegel is an ass...

What if a simple conversation in the emergency room could reveal who’s most at risk for PTSD before symptoms even begin? Katharina Schultebraucks, PhD, shares her innovative work on using machine learning to forecast mental health outcomes and explains how AI could revolutionize how we detect, prevent, and treat psychiatric disorders. Dr. Schultebraucks is Co-Director of the Computational Psychiatry Program and Associate Professor ...

How do you help a child with ADHD stay organized, on task, and confident in school? Richard Gallagher, PhD, a child and adolescent psychologist at NYU Langone Health, shares groundbreaking research on organizational skills training for children with ADHD—a behavioral treatment that’s changing lives and improving classroom performance. This episode dives into how executive functioning challenges manifest in real life, the strengths ...

ADHD isn’t just a childhood condition—many adults go undiagnosed for years. Lenard Adler, MD, Director of the Adult ADHD Program at NYU Langone Health, breaks down the nuances of ADHD in adults, the challenges of proper diagnosis, and the latest treatments available. Learn about his research, the screening tools his team has developed, and what’s on the horizon for adult ADHD care.

🔍 Topics Covered:

00:00 Introduction
00:44 Dr. ...

Despite affecting more Americans than diabetes, substance use is often left out of routine medical care. In this episode, NYU Langone Health’s Jennifer McNeely, MD—a clinician investigator, primary care and addiction medicine physician—explains why that must change. From the surprising history behind addiction’s exclusion from mainstream medicine to the innovative screening tools shaping the future of care, this conversation is a m...

What makes addiction treatment truly effective? Behavioral scientist Charles Neighbors, MBA, PhD, shares groundbreaking research on the importance of therapeutic relationships, harm reduction, and human connection—love!—in treating substance use disorders. Dr. Neighbors is an Associate Professor in the Departments of Population Health, and Psychiatry at NYU Grossman School of Medicine.

💡 Topics Covered

00:00 Introduction to Dr. Char...

For the final episode of Season 2, we're joined by Dr. Samuele Cortese, Professor of Child and Adolescent Psychiatry at the University of Southampton (UK) and Adjunct Full Professor at NYU Langone. Together we explore the intersection of pediatric ADHD and precision psychiatry, including the disorder’s genetic underpinnings and evolving treatment options.

00:00 Introduction
00:54 Dr. Cortese's Research Journe...

Dr. Timothy Wilens is a Professor of Psychiatry at Harvard Medical School and Chief of the Division of Child and Adolescent Psychiatry at Massachusetts General Hospital. His research interest include the relationship between ADHD, bipolar disorder, and substance use disorders; ADHD pharmacotherapy; and stimulant medication misuse.

On this episode, Dr. Wilens discusses the importance of early diagnosis and intervention in A...

Dr. Ira Glick is Professor Emeritus of Psychiatry and Behavioral Sciences at Stanford University Medical Center, where he has served as director of the Schizophrenia Research Clinic. On this episode, he discusses his research journey, which began in the 1960s and followed a shift from psychoanalysis to biological psychiatry. He addresses the broken social safety net for schizophrenia patients, including the controversial topic of t...